Back to results
US 6,294,537 B1Granted
Compounds which are specific antagonists of the human NK3 receptor and their use as medicinal products and diagnostic tools
AssigneeSanofi-Synthelabo
InventorsDaniel Bichon, Patrick Gueule, Didier Van Broeck, Xavier Emonds-Alt, Vincenzo Proietto
Life of this patent
Estimating the term…
Abstract
A method for treating diseases which involve interaction of neurokinin B with NK3 receptors in humans. The method comprises administering a therapeutically effective amount of a NK3 antagonist compound having the formula: in which: R1 and R11 together represent a —(CH2)3-group.
Claims21
A method of treating a disease involving neurokinin B wherein antagonism of the NK3 receptor is required, which comprises administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of:
- 1-benzoyl-3-(3,4-chlorophenyl)-3-[3-(4-(acetyl-N-methylamino)-4-phenylpiperid-1-yl)-propyl]piperidine,
- 1-benzoyl-3-(3,4-dichlorophenyl)-3-[3-(4-(propionyl-N-methylamino)-4-phenylpiperid-1-yl)propyl]piperidine,
- 1-benzoyl-3-(3,4-dichlorophenyl)-3-[3-(4-(butyryl-N-methylamino)-4-phenylpiperid-1-yl)-propyl]piperidine,
- 1-benzoyl-3-(3,4-dichlorophenyl)-3-[3-(4-(isobutyryl-N-methylamino)-4-phenyl-piperid-1-yl)propyl]piperidine,
- 1-benzoyl-3-(3,4-dichlorophenyl)-3-[3-(4-(valeryl-N-methylamino)-4-phenylpiperid-1-yl)-propyl]piperidine,
- 1-benzoyl-3-(3,4-dichlorophenyl)-3-[3-(4-(isovaleryl-N-methylamino)-4-phenylpiperid-1-yl)propyl]piperidine,
- 1-benzoyl-3-(3,4-dichlorophenyl)-3-[3-(4-(pivaloyl-N-methylamino)-4-phenylpiperid-1-yl)-propyl]piperidine,
- and pharmaceutically acceptable salts thereof,
- wherein said compound is in the form of a (+) enantiomer.
6 more elements
Dependencies are inferred from the claim text.